Neuroimaging Endpoints in Amyotrophic Lateral Sclerosis

Neurotherapeutics

Volumn 14, Issue 1, 2017, Pages 11-23

  Menke, Ricarda A L ^a   Agosta, Federica ^b   Grosskreutz, Julian ^c   Filippi, Massimo ^b   Turner, Martin R ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Amyotrophic lateral sclerosis; biomarker; magnetic resonance imaging; motor neuron disease; trial

Indexed keywords

AGING; AMYOTROPHIC LATERAL SCLEROSIS; DISEASE COURSE; DISEASE MARKER; DRUG EFFECT; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GRAY MATTER; HUMAN; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; THERAPY EFFECT; WHITE MATTER; ANIMAL; BIOASSAY; BRAIN; BRAIN MAPPING; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED DIAGNOSIS; DIAGNOSTIC IMAGING; DIFFUSION TENSOR IMAGING; DISEASE MODEL; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES;

BIOLOGICAL MARKER;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; BIOMARKERS; BRAIN; BRAIN MAPPING; CLINICAL TRIALS AS TOPIC; DIFFUSION TENSOR IMAGING; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENDPOINT DETERMINATION; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; NEUROIMAGING; POSITRON-EMISSION TOMOGRAPHY;

EID: 84991627940     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-016-0484-9     Document Type: Review

References (136)

1. Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet 2011;377:942-955.
2. Turner MR, Swash M. The expanding syndrome of amyotrophic lateral sclerosis: a clinical and molecular odyssey. J Neurol Neurosurg Psychiatry 2015;86:667-73.
3. Benatar M, Wuu J. Presymptomatic studies in ALS: rationale, challenges, and approach. Neurology 2012;79:1732-1739.
4. Turner MR, Brockington A, Scaber J, et al. Pattern of spread and prognosis in lower limb-onset ALS. Amyotroph Lateral Scler 2010;11:369-373.
5. Ravits JM, La Spada AR. ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology 2009;73:805-811.
6. Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293-299.
7. Swank RL, Putnam TJ. Amyotrophic lateral sclerosis and related conditions: a clinical analysis. Arch Neurol Psychiatry 1943;49:151-177.
8. Turner MR, Parton MJ, Shaw CE, et al. Prolonged survival in motor neuron disease: a descriptive study of the King's database 1990–2002. J Neurol Neurosurg Psychiatry 2003;74:995-997.
9. Chio A, Calvo A, Moglia C, et al. Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry 2011;82:740-746.
10. Elamin M, Bede P, Byrne S, et al. Cognitive changes predict functional decline in ALS: A population-based longitudinal study. Neurology 2013;80:1590-1597.
11. Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 1999;169:13-21.
12. Proudfoot M, Jones A, Talbot K, et al. The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset. Amyotroph Lateral Scler Frontotemporal Degener 2016;17:414-425.
13. Menon P, Geevasinga N, Yiannikas C, et al. Sensitivity and specificity of threshold tracking transcranial magnetic stimulation for diagnosis of amyotrophic lateral sclerosis: a prospective study. Lancet Neurol 2015;14:478-484.
14. Lu CH, Macdonald-Wallis C, Gray E, et al. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology 2015;84:2247-2257.
15. Shefner JM, Watson ML, Simionescu L, et al. Multipoint incremental motor unit number estimation as an outcome measure in ALS. Neurology 2011;77:235-241.
16. Rutkove SB, Caress JB, Cartwright MS, et al. Electrical impedance myography as a biomarker to assess ALS progression. Amyotroph Lateral Scler 2012;13:439-445.
17. Brettschneider J, Del Tredici K, Toledo JB, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol 2013;74:20-38.
18. Polymenidou M, Cleveland DW. The seeds of neurodegeneration: prion-like spreading in ALS. Cell 2011;147:498-508.
19. Braak H, Brettschneider J, Ludolph AC, et al. Amyotrophic lateral sclerosis—a model of corticofugal axonal spread. Nat Rev Neurol 2013;9:708-714.
20. Turner MR, Agosta F, Bede P, et al. Neuroimaging in amyotrophic lateral sclerosis. Biomark Med 2012;6:319-337.
21. Babalola KO, Patenaude B, Aljabar P, et al. An evaluation of four automatic methods of segmenting the subcortical structures in the brain. Neuroimage 2009;47:1435-1447.
22. Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002;33:341-355.
23. Good CD, Johnsrude IS, Ashburner J, et al. A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage 2001;14:21-36.
24. Ashburner J, Friston KJ. Voxel-based morphometry—the methods. Neuroimage 2000;11:805-821.
25. Hartung V, Prell T, Gaser C, et al. Voxel-based MRI intensitometry reveals extent of cerebral white matter pathology in amyotrophic lateral sclerosis. PLOS ONE 2014;9:e104894.
26. Lebihan D, Breton E, Lallemand D, et al. Mr Imaging of intravoxel incoherent motions—application to diffusion and perfusion in neurologic disorders. Radiology. 1986;161:401-407.
27. Basser PJ, Mattiello J, LeBihan D. Estimation of the effective self-diffusion tensor from the NMR spin echo. J Magn Reson Ser B 1994;103:247-254.
28. Beaulieu C. The basis of anisotropic water diffusion in the nervous system—a technical review. NMR Biomed 2002;15:435-455.
29. Douaud G, Jbabdi S, Behrens TE, et al. DTI measures in crossing-fibre areas: increased diffusion anisotropy reveals early white matter alteration in MCI and mild Alzheimer's disease. Neuroimage 2011;55:880-890.
30. Smith SM, Jenkinson M, Johansen-Berg H, et al. Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage 2006;31:1487-1505.
31. Sporns O, Zwi JD. The small world of the cerebral cortex. Neuroinformatics 2004;2:145-162.
32. Iturria-Medina Y, Canales-Rodriguez EJ, Melie-Garcia L, et al. Characterizing brain anatomical connections using diffusion weighted MRI and graph theory. Neuroimage 2007;36:645-660.
33. Damoiseaux JS, Rombouts SARB, Barkhof F, et al. Consistent resting-state networks across healthy subjects. Proc Natl Acad Sci U S A 2006;103:13848-13853.
34. Smith SM, Fox PT, Miller KL, et al. Correspondence of the brain's functional architecture during activation and rest. Proc Natl Acad Sci U S A 2009;106:13040-13045.
35. Cole DM, Smith SM, Beckmann CF. Advances and pitfalls in the analysis and interpretation of resting-state FMRI data. Front Syst Neurosci 2010;4:8.
36. Beckmann CF, Smith SM. Probabilistic independent component analysis for functional magnetic resonance imaging. IEEE Trans Med Imaging 2004;23:137-152.
37. Beckmann CF, DeLuca M, Devlin JT, et al. Investigations into resting-state connectivity using independent component analysis. Philos Trans R Soc Lond B Biol Sci 2005;360:1001-1013.
38. Turner MR, Leigh PN. Positron emission tomography (PET)—its potential to provide surrogate markers in ALS. Amyotroph Lateral Scle rOther Motor Neuron Disord 2000;1(Suppl. 2):S17-S22.
39. Evans MC, Couch Y, Sibson N, et al. Inflammation and neurovascular changes in amyotrophic lateral sclerosis. Mol Cell Neurosci 2012;53:34-41.
40. Turner MR, Benatar M. Ensuring continued progress in biomarkers for amyotrophic lateral sclerosis. Muscle Nerve 2015;51:14-18.
41. Huynh W, Simon NG, Grosskreutz J, et al. Assessment of the upper motor neuron in amyotrophic lateral sclerosis. Clin Neurophysiol 2016;127:2643-2660.
42. Abe O, Yamada H, Masutani Y, et al. Amyotrophic lateral sclerosis: diffusion tensor tractography and voxel-based analysis. NMR Biomed 2004;17:411-416.
43. Sach M, Winkler G, Glauche V, et al. Diffusion tensor MRI of early upper motor neuron involvement in amyotrophic lateral sclerosis. Brain 2004;127:340-350.
44. Cosottini M, Giannelli M, Siciliano G, et al. Diffusion-tensor MR imaging of corticospinal tract in amyotrophic lateral sclerosis and progressive muscular atrophy. Radiology 2005;237:258-264.
45. Sage CA, Peeters RR, Gorner A, et al. Quantitative diffusion tensor imaging in amyotrophic lateral sclerosis. Neuroimage 2007;34:486-499.
46. Thivard L, Pradat PF, Lehericy S, et al. Diffusion tensor imaging and voxel based morphometry study in amyotrophic lateral sclerosis: relationships with motor disability. J Neurol Neurosurg Psychiatry 2007;78:889-892.
47. Iwata NK, Aoki S, Okabe S, et al. Evaluation of corticospinal tracts in ALS with diffusion tensor MRI and brainstem stimulation. Neurology 2008;70:528-532.
48. Agosta F, Pagani E, Petrolini M, et al. Assessment of white matter tract damage in patients with amyotrophic lateral sclerosis: a diffusion tensor MR imaging tractography study. AJNR Am J Neuroradiol 2010;31:1457-1461.
49. van der Graaff MM, Sage CA, Caan MW, et al. Upper and extra-motoneuron involvement in early motoneuron disease: a diffusion tensor imaging study. Brain 2011;134:1211-1228.
50. Menke RA, Korner S, Filippini N, et al. Widespread grey matter pathology dominates the longitudinal cerebral MRI and clinical landscape of amyotrophic lateral sclerosis. Brain 2014;137:2546-2555.
51. Blain CR, Brunton S, Williams VC, et al. Differential corticospinal tract degeneration in homozygous 'D90A' SOD-1 ALS and sporadic ALS. J Neurol Neurosurg Psychiatry 2011;82:843-849.
52. Verstraete E, Polders DL, Mandl RC, et al. Multimodal tract-based analysis in ALS patients at 7T: a specific white matter profile? Amyotroph Lateral Scler Frontotemporal Degener 2014;15:84-92.
53. Filippini N, Douaud G, Mackay CE, et al. Corpus callosum involvement is a consistent feature of amyotrophic lateral sclerosis. Neurology 2010;75:1645-1652.
54. Chapman MC, Jelsone-Swain L, Johnson TD, et al. Diffusion tensor MRI of the corpus callosum in amyotrophic lateral sclerosis. J Magn Reson Imaging 2014;39:641-647.
55. Iwata NK, Kwan JY, Danielian LE, et al. White matter alterations differ in primary lateral sclerosis and amyotrophic lateral sclerosis. Brain 2011;134:2642-2655.
56. Senda J, Kato S, Kaga T, et al. Progressive and widespread brain damage in ALS: MRI voxel-based morphometry and diffusion tensor imaging study. Amyotroph Lateral Scler 2011;12:59-69.
57. Canu E, Agosta F, Galantucci S, et al. Extramotor damage is associated with cognition in primary lateral sclerosis patients. PLOS ONE 2013;8:e82017.
58. Agosta F, Ferraro PM, Riva N, et al. Structural brain correlates of cognitive and behavioral impairment in MND. Hum Brain Mapp 2016;37:1614-1626.
59. Ng MC, Ho JT, Ho SL, Lee R, Li G, Cheng TS, et al. Abnormal diffusion tensor in nonsymptomatic familial amyotrophic lateral sclerosis with a causative superoxide dismutase 1 mutation. J Magn Reson Imaging 2008;27(1):8-13.
60. Vucic S, Winhammar JM, Rowe DB, et al. Corticomotoneuronal function in asymptomatic SOD-1 mutation carriers. Clin Neurophysiol 2010;121:1781-1785.
61. Foerster BR, Dwamena BA, Petrou M, et al. Diagnostic accuracy using diffusion tensor imaging in the diagnosis of ALS: a meta-analysis. Acad Radiol 2012;19:1075-1086.
62. Grosskreutz J, Kaufmann J, Fradrich J, et al. Widespread sensorimotor and frontal cortical atrophy in amyotrophic lateral sclerosis. BMC Neurol 2006;6:17.
63. Agosta F, Pagani E, Rocca MA, et al. Voxel-based morphometry study of brain volumetry and diffusivity in amyotrophic lateral sclerosis patients with mild disability. Hum Brain Mapp 2007;28:1430-1438.
64. Roccatagliata L, Bonzano L, Mancardi G, et al. Detection of motor cortex thinning and corticospinal tract involvement by quantitative MRI in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2009;10:47-52.
65. Raaphorst J, van Tol MJ, de Visser M, et al. Prose memory impairment in amyotrophic lateral sclerosis patients is related to hippocampus volume. Eur J Neurol 2015;22:547-554.
66. Shen D, Cui L, Fang J, et al. Voxel-wise meta-analysis of gray matter changes in amyotrophic lateral sclerosis. Front Aging Neurosci 2016;8:64.
67. Agosta F, Valsasina P, Riva N, et al. The cortical signature of amyotrophic lateral sclerosis. PLOS ONE 2012;7:e42816.
68. Verstraete E, Veldink JH, Hendrikse J, et al. Structural MRI reveals cortical thinning in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2012;83:383-388.
69. Schuster C, Kasper E, Machts J, et al. Focal thinning of the motor cortex mirrors clinical features of amyotrophic lateral sclerosis and their phenotypes: a neuroimaging study. J Neurol 2013;260:2856-2864.
70. Walhout R, Westeneng HJ, Verstraete E, et al. Cortical thickness in ALS: towards a marker for upper motor neuron involvement. J Neurol Neurosurg Psychiatry 2015;86:288-294.
71. Douaud G, Filippini N, Knight S, et al. Integration of structural and functional magnetic resonance imaging in amyotrophic lateral sclerosis. Brain 2011;134:3470-3479.
72. Menke RAL, Gray E, Lu C-H, et al. CSF neurofilament light chain reflects corticospinal tract degeneration in ALS. Ann Clin Transl Neurol 2015;2:748-755.
73. Rohrer JD, Nicholas JM, Cash DM, et al. Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurol 2015;14:253-262.
74. Walhout R, Schmidt R, Westeneng HJ, et al. Brain morphologic changes in asymptomatic C9orf72 repeat expansion carriers. Neurology 2015;85:1780-1788.
75. Schoenfeld MA, Tempelmann C, Gaul C, et al. Functional motor compensation in amyotrophic lateral sclerosis. J Neurol 2005;252:944-952.
76. Mohammadi B, Kollewe K, Samii A, et al. Functional neuroimaging at different disease stages reveals distinct phases of neuroplastic changes in amyotrophic lateral sclerosis. Hum Brain Mapp 2011;32:750-758.
77. Witiuk K, Fernandez-Ruiz J, McKee R, et al. Cognitive deterioration and functional compensation in ALS measured with fMRI using an inhibitory task. J Neurosci 2014;34:14260-14271.
78. Raaphorst J, van Tol MJ, Groot PF, et al. Prefrontal involvement related to cognitive impairment in progressive muscular atrophy. Neurology 2014;83:818-825.
79. Mohammadi B, Kollewe K, Samii A, et al. Changes of resting state brain networks in amyotrophic lateral sclerosis. Exp Neurol 2009;217:147-153.
80. Jelsone-Swain LM, Fling BW, Seidler RD, et al. Reduced interhemispheric functional connectivity in the motor cortex during rest in limb-onset amyotrophic lateral sclerosis. Front Syst Neurosci 2010;4:158.
81. Tedeschi G, Trojsi F, Tessitore A, et al. Interaction between aging and neurodegeneration in amyotrophic lateral sclerosis. Neurobiol Aging 2012;33:886-898.
82. Agosta F, Valsasina P, Absinta M, et al. Sensorimotor functional connectivity changes in amyotrophic lateral sclerosis. Cereb Cortex 2011;21:2291-2298.
83. Agosta F, Canu E, Valsasina P, et al. Divergent brain network connectivity in amyotrophic lateral sclerosis. Neurobiol Aging 2013;34:419-427.
84. Chenji S, Jha S, Lee D, et al. Investigating default mode and sensorimotor network connectivity in amyotrophic lateral sclerosis. PLOS ONE 2016;11:e0157443.
85. Schmidt R, Verstraete E, de Reus MA, et al. Correlation between structural and functional connectivity impairment in amyotrophic lateral sclerosis. Hum Brain Mapp 2014;35:4386-4395.
86. Menke RA, Proudfoot M, Wuu J, et al. Increased functional connectivity common to symptomatic amyotrophic lateral sclerosis and those at genetic risk. J Neurol Neurosurg Psychiatry 2016;87:580-588.
87. Dalakas MC, Hatazawa J, Brooks RA, et al. Lowered cerebral glucose-utilization in amyotrophic-lateral-sclerosis. Ann Neurol 1987;22:580-586.
88. Kew JJ, Leigh PN, Playford ED, et al. Cortical function in amyotrophic lateral sclerosis. A positron emission tomography study. Brain 1993;116:655-680.
89. Turner MR, Cagnin A, Turkheimer FE, et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [C-11](R)-PK11195 positron emission tomography study. Neurobiol Dis 2004;15:601-609.
90. Zurcher NR, Loggia ML, Lawson R, et al. Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: Assessed with [(11)C]-PBR28. Neuroimage Clin 2015;7:409-414.
91. Lloyd CM, Richardson MP, Brooks DJ, et al. Extramotor involvement in ALS: PET studies with the GABA(A) ligand [(11)C]flumazenil. Brain 2000;123:2289-2296.
92. Turner MR, Hammers A, Al-Chalabi A, et al. Distinct cerebral lesions in sporadic and 'D90A' SOD1 ALS: studies with [11C]flumazenil PET. Brain 2005;128:1323-1329.
93. Turner MR, Rabiner EA, Hammers A, et al. (2005) [11C]-WAY100635 PET demonstrates marked 5-HT1A receptor changes in sporadic ALS. Brain 28:896-905.
94. Lanctot KL, Herrmann N, Ganjavi H, et al. Serotonin-1A receptors in frontotemporal dementia compared with controls. Psychiatry Res 2007;156:247-250.
95. Majo VJ, Prabhakaran J, Mann JJ, et al. PET and SPECT tracers for glutamate receptors. Drug Discov Today 2013;18:173-184.
96. Brownell AL, Kuruppu D, Kil KE, et al. PET imaging studies show enhanced expression of mGluR5 and inflammatory response during progressive degeneration in ALS mouse model expressing SOD1-G93A gene. J Neuroinflamm 2015;12:217.
97. Pioro EP, Antel JP, Cashman NR, et al. Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo. Neurology 1994;44:1933-1938.
98. Stagg CJ, Knight S, Talbot K, et al. Whole-brain magnetic resonance spectroscopic imaging measures are related to disability in ALS. Neurology 2013;80:610-615.
99. Foerster BR, Callaghan BC, Petrou M, et al. Decreased motor cortex gamma-aminobutyric acid in amyotrophic lateral sclerosis. Neurology 2012;78:1596-1600.
100. Pioro EP, Majors AW, Mitsumoto H, et al. 1H-MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla. Neurology 1999;53:71-79.
101. Chio A, Logroscino G, Hardiman O, et al. Prognostic factors in ALS: A critical review. Amyotroph Lateral Scler 2009;10:310-323.
102. Muller HP, Unrath A, Huppertz HJ, et al. Neuroanatomical patterns of cerebral white matter involvement in different motor neuron diseases as studied by diffusion tensor imaging analysis. Amyotroph Lateral Scler 2012;13:254-264.
103. Agosta F, Galantucci S, Riva N, et al. Intrahemispheric and interhemispheric structural network abnormalities in PLS and ALS. Hum Brain Mapp 2014;35:1710-1722.
104. Cardenas-Blanco A, Machts J, Acosta-Cabronero J, et al. Central white matter degeneration in bulbar- and limb-onset amyotrophic lateral sclerosis. J Neurol 2014;261:1961-1967.
105. Menke RA, Abraham I, Thiel CS, et al. Fractional anisotropy in the posterior limb of the internal capsule and prognosis in amyotrophic lateral sclerosis. Arch Neurol 2012;69:1493-1499.
106. Blain CR, Williams VC, Johnston C, et al. A longitudinal study of diffusion tensor MRI in ALS. Amyotroph Lateral Scler 2007;8:348-355.
107. Agosta F, Rocca MA, Valsasina P, et al. A longitudinal diffusion tensor MRI study of the cervical cord and brain in amyotrophic lateral sclerosis patients. J Neurol Neurosurg Psychiatry 2009;80:53-55.
108. El Mendili MM, Cohen-Adad J, Pelegrini-Issac M, et al. Multi-parametric spinal cord MRI as potential progression marker in amyotrophic lateral sclerosis. PLOS ONE 2014;9:e95516.
109. Agosta F, Pagani E, Petrolini M, et al. MRI predictors of long-term evolution in amyotrophic lateral sclerosis. Eur J Neurosci 2010;32:1490-1496.
110. Zhang Y, Schuff N, Woolley SC, et al. Progression of white matter degeneration in amyotrophic lateral sclerosis: A diffusion tensor imaging study. Amyotroph Lateral Scler 2011;12:421-429.
111. Keil C, Prell T, Peschel T, et al. Longitudinal diffusion tensor imaging in amyotrophic lateral sclerosis. BMC Neurosci 2012;13:141.
112. Verstraete E, Veldink JH, van den Berg LH, et al. Structural brain network imaging shows expanding disconnection of the motor system in amyotrophic lateral sclerosis. Hum Brain Mapp 2014;35:1351-1361.
113. Agosta F, Gorno-Tempini ML, Pagani E, et al. Longitudinal assessment of grey matter contraction in amyotrophic lateral sclerosis: a tensor based morphometry study. Amyotroph Lateral Scler 2009;10:168-174.
114. Schuster C, Kasper E, Machts J, et al. Longitudinal course of cortical thickness decline in amyotrophic lateral sclerosis. J Neurol 2014;261:1871-1880.
115. Westeneng HJ, Verstraete E, Walhout R, et al. Subcortical structures in amyotrophic lateral sclerosis. Neurobiol Aging 2015;36:1075-1082.
116. Kwan JY, Meoded A, Danielian LE, et al. Structural imaging differences and longitudinal changes in primary lateral sclerosis and amyotrophic lateral sclerosis. Neuroimage Clin 2012;2:151-160.
117. Cardenas-Blanco A, Machts J, Acosta-Cabronero J, et al. Structural and diffusion imaging versus clinical assessment to monitor amyotrophic lateral sclerosis. Neuroimage Clin 2016;11:408-414.
118. Suhy J, Miller RG, Rule R, et al. Early detection and longitudinal changes in amyotrophic lateral sclerosis by (1)H MRSI. Neurology 2002;58:773-779.
119. Rule RR, Suhy J, Schuff N, et al. Reduced NAA in motor and non-motor brain regions in amyotrophic lateral sclerosis: a cross-sectional and longitudinal study. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5:141-149.
120. Unrath A, Ludolph AC, Kassubek J. Brain metabolites in definite amyotrophic lateral sclerosis. A longitudinal proton magnetic resonance spectroscopy study. J Neurol 2007;254:1099-1106.
121. Weiner MW, Veitch DP, Aisen PS, et al. Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimers Dement 2015;11:865-884.
122. Merlo Pich E, Jeromin A, Frisoni GB, et al. Imaging as a biomarker in drug discovery for Alzheimer's disease: is MRI a suitable technology? Alzheimers Res Ther 2014;6:51.
123. Burciu RG, Chung JW, Shukla P, et al. Functional MRI of disease progression in Parkinson disease and atypical parkinsonian syndromes. Neurology 2016;87:709-717.
124. Rosas HD, Doros G, Gevorkian S, et al. PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease. Neurology 2014;82:850-857.
125. Zhang Y, Schuff N, Woolley SC, et al. Progression of white matter degeneration in amyotrophic lateral sclerosis: a diffusion tensor imaging study. Amyotroph Lateral Scler 2011;12:421-429.
126. Weidman EK, Dean KE, Rivera W, et al. MRI safety: a report of current practice and advancements in patient preparation and screening. Clin Imaging 2015;39:935-937.
127. Gunter JL, Bernstein MA, Borowski BJ, et al. Measurement of MRI scanner performance with the ADNI phantom. Med Phys 2009;36:2193-2205.
128. Pagani E, Hirsch JG, Pouwels PJ, et al. Intercenter differences in diffusion tensor MRI acquisition. J Magn Reson Imaging 2010;31:1458-1468.
129. Brueggen K, Grothe MJ, Dyrba M, et al. The European DTI Study on Dementia—a multicenter DTI and MRI study on Alzheimer's disease and mild cognitive impairment. Neuroimage 2016 Apr 2.
130. Muller HP, Turner MR, Grosskreutz J, et al. A large-scale multicentre cerebral diffusion tensor imaging study in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2016;87:570-579.
131. Duning T, Kloska S, Steinstrater O, et al. Dehydration confounds the assessment of brain atrophy. Neurology 2005;64:548-550.
132. Smith SM, Zhang Y, Jenkinson M, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002;17:479-489.
133. Proudfoot M, Woolrich MW, Nobre AC, et al. Magnetoencephalography. Pract Neurol 2014;14:336-343.
134. Proudfoot M, Rohenkohl G, Quinn A, et al. Altered cortical beta-band oscillations reflect motor system degeneration in amyotrophic lateral sclerosis. Hum Brain Mapp 2016 Sep 13.
135. Miller KL, Stagg CJ, Douaud G, et al. Diffusion imaging of whole, post-mortem human brains on a clinical MRI scanner. Neuroimage 2011;57:167-181.
136. Kassubek J, Muller HP, Del Tredici K, et al. Diffusion tensor imaging analysis of sequential spreading of disease in amyotrophic lateral sclerosis confirms patterns of TDP-43 pathology. Brain 2014;137:1733-1740.